Journal
RESEARCH IN VETERINARY SCIENCE
Volume 99, Issue -, Pages 23-29Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.rvsc.2014.12.001
Keywords
Incretins; Cats; Diabetes mellitus; Exenatide; Sitagliptin
Categories
Ask authors/readers for more resources
Incretin analogues and inhibitors of the breakdown of endogenous incretins are antidiabetic drugs that increase beta-cell proliferation and glucose-stimulated insulin secretion in rodents and humans. Objectives were to test whether exenatide, exenatide extended-release, and sitagliptin can be safely used in cats, to identify the most effective drug, and to test the effects of prolonged exenatide extended-release administration. Three cats each were given exenatide (0.2-2 mu g/kg, q12h, subcutaneously, 5 days), exenatide extended-release (40-400 mu g/kg, subcutaneously, once), and sitagliptin (1-10 mg/kg, q24h, orally, 5 days). Before and after treatment, glucose, insulin and glucagon areas under the curve (AUC) were assessed by meal response tests (MRT). Exenatide increased insulin AUC by 224%, 258%, 331% and 93%, exenatide extended-release by 127%, 169%, 178% and 95%, and sitagliptin by 32%, 69%, 62%, and 43%, respectively. The tested drugs are safe to use in cats and enhance insulin secretion. Incretin-based therapy may be beneficial in cats with diabetes mellitus. (C) 2014 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available